olivLaw · US equity research
Advanced Biomed Inc. ADVB
Services-Medical Laboratories · SIC 8071 · Vertical: Services-Medical Laboratories (SIC 8071)
Advanced Biomed Inc. (ADVB) has fully exited its biomedical business of cancer detection from blood samples and has refocused on FinTruth, an AI platform that verifies financial analysis produced by language models. The company reported revenue of $127,637 in fiscal 2026, while the $6,261,276 loss from continuing operations shows the shift to the new model is still at an early stage.
At the close of 05 Nov 2026, Advanced Biomed Inc. (ADVB) stock was 1.90 USD (−9.52% on the day), with market capitalisation 3.1 m USD, P/E 0.4 on diluted EPS of 5.33 USD over the last 12 months, beta 0.46, 52-week range 1.90–18.98 USD. Latest reported quarter (Q4 2026): net income of 695.0 k USD, diluted EPS 0.44 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 20.1
- oversold (≤ 30)
- Bollinger (20, 2)
- 1.21 – 5.79
- in the lower half of the band · %B 0.15 · band width 130.7%
- SMA 50 / 200
- 5.99 / 5.84
- mixed trend
- MACD (12, 26, 9)
- -1.14 / -1.10
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −70.2% | −5.9% | −64.3 pp | — |
| 3 months | −74.5% | −4.6% | −69.8 pp | — |
| 6 months | −73.6% | +0.2% | −73.8 pp | — |
| Year to date | −67.5% | +7.4% | −74.9 pp | — |
| 1 year | −78.6% | +8.2% | −86.8 pp | −5.8% |
| 3 years | unavailable | +68.4% | unavailable | +59.6% |
| 5 years | unavailable | +56.5% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q4 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Research & development | 181.7 k | 212.4 k | 220.0 k | 309.7 k | 236.0 k | 186.3 k | 243.2 k | — |
| Depreciation & amortisation | 102.2 k | -56.8 k ≈ | 22.5 k ≈ | 275.9 k | 48.0 k | -12.9 k ≈ | 9.3 k ≈ | — |
| Pre-tax income | -265.6 k | -579.5 k | -1.2 m | 675.6 k | -386.9 k | 7.0 m | -488.9 k | -12.5 m |
| Net income | -265.6 k | -907.9 k | -1.4 m | -701.6 k | -386.9 k | 6.9 m | -488.9 k | 695.0 k |
| Diluted EPS | -0.01 | -0.05 | -1.35 | -0.65 ≈ | -0.02 | 0.31 | -0.38 | 0.44 ≈ |
| Operating cash flow | -29.7 k | -841.8 k ≈ | -3.4 m ≈ | -1.5 m | -610.3 k | -513.6 k ≈ | -239.8 k ≈ | -583.3 k |
| Capex | 20.0 k | -10.7 k ≈ | 2.2 k ≈ | 20.1 k | 1.8 k | 12.9 k ≈ | 1.3 k ≈ | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 1-quarter history (min 13.1, median 13.1, max 13.1; quarters with earnings only).
Fiscal years
| Fiscal year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | unavailable | unavailable | 127.6 k |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | -2.8 m | -3.3 m | 6.7 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -0.14 | -3.18 | 5.33 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | 5,231.3% |
| Free cash flow | -2.2 m | -5.9 m | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 30 Jun 2026
- Cash
- 385.5 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 12.3 m USD
- Total assets
- 13.8 m USD
- Debt / equity
- unavailable
- Current ratio
- 9.33x
- ROE
- 84.8%
- ROA
- 36.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|
| Revenue | — | — | 127.6 k | SEC (XBRL)· 13 Oct 2026verified |
| Research & development | 880.2 k | 909.8 k | — | SEC (XBRL)· 08 Oct 2025verified |
| Operating income | — | -1.1 m | -6.2 m | SEC (XBRL)· 13 Oct 2026verified |
| Depreciation & amortisation | 399.6 k | 343.8 k | — | SEC (XBRL)· 08 Oct 2025verified |
| EBITDA | — | -742.6 k ≈ | — | SEC (XBRL)· 13 Oct 2026derived |
| Pre-tax income | -2.8 m | -1.1 m | -6.3 m | SEC (XBRL)· 13 Oct 2026verified |
| Income tax | — | — | -1.2 k | SEC (XBRL)· 13 Oct 2026verified |
| Net income | -2.8 m | -3.3 m | 6.7 m | SEC (XBRL)· 13 Oct 2026verified |
| Diluted EPS | -0.14 | -3.18 | 5.33 | SEC (XBRL)· 13 Oct 2026verified |
| Weighted average diluted shares | 20.0 m | 1.0 m | 1.3 m | SEC (XBRL)· 13 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|
| Cash | 2.6 m | 31.1 k | 385.5 k | SEC (XBRL)· 13 Oct 2026verified |
| Current assets | 3.1 m | 22.4 m | 13.7 m | SEC (XBRL)· 13 Oct 2026verified |
| Property, plant & equipment, net | 524.5 k | 125.2 k | — | SEC (XBRL)· 13 Feb 2026verified |
| Intangibles (excl. goodwill) | 119.0 k | — | — | SEC (XBRL)· 15 Apr 2025verified |
| Total assets | 4.5 m | 22.9 m | 13.8 m | SEC (XBRL)· 13 Oct 2026verified |
| Accounts payable | 620.5 k | 358.2 k | 1.5 m | SEC (XBRL)· 13 Oct 2026verified |
| Current liabilities | 2.7 m | 19.2 m | 1.5 m | SEC (XBRL)· 13 Oct 2026verified |
| Total liabilities | 2.8 m | 19.4 m | 1.5 m | SEC (XBRL)· 13 Oct 2026verified |
| Equity | 1.7 m † | 3.5 m † | 12.3 m † | SEC (XBRL)· 13 Oct 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -2.1 m | -5.8 m | -1.9 m | SEC (XBRL)· 13 Oct 2026verified |
| Capex | 74.1 k | 31.7 k | — | SEC (XBRL)· 08 Oct 2025verified |
| Free cash flow | -2.2 m ≈ | -5.9 m ≈ | — | SEC (XBRL)· 08 Oct 2025derived |
| Investing cash flow | -74.1 k | -31.7 k | -2.5 m | SEC (XBRL)· 13 Oct 2026verified |
| Financing cash flow | 1.9 m | 5.9 m | 2.0 m | SEC (XBRL)· 13 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 3.1 m USD
Key indicators
Coverage and freshness
Score by group
35% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 147.13 – 164.55 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E147.13 – 164.55 (Mid 158.86)3 companies used · median multiple 29.8x · quartiles 27.6x – 30.9xCDNA, DGX, LH
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 5,231.3% | 100 (vs peers) | 18% |
| FCF conversion · Quality | -29.7% | 0 (on a fixed band) | 18% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 9.3x | 100 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | 0.4x | 100 (vs peers) | 29% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -63.2% | 0 (on a fixed band) | 24% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality50/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation56/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Advanced Biomed Inc. (ADVB). Latest full fiscal year: 2026; data up to 2026-06-30.
Figures computed from the financial statements: revenue 127.6 k USD in 2026; net margin 5,231.3%; ROE 84.8%.
The estimated value range is 147.13–164.55 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 158.86 USD, the price of 1.90 USD leaves a potential of 8,261.0% (value / price − 1) and a margin of safety of 98.8% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 5,231.3%
- Current ratio: 9.3x
- P/E (TTM): 0.4x
- The price is below the estimated value range
What contradicts it
- FCF conversion: -29.7%
- FCF yield: -63.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Medical Laboratories (SIC 8071) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRANatera, Inc. | 52.7 bn | — | -10.6% | -5.7% | +35.9% | +52% / +550% |
| LHLabcorp Holdings Inc. | 29.5 bn | 29.8 | 11.4% | 6.9% | +7.2% | +35% / +67% |
| DGXQuest Diagnostics Inc | 28.0 bn | 25.4 | 15.2% | 9.5% | +11.8% | +35% / +86% |
| GHGuardant Health, Inc. | 20.8 bn | — | — | -37.9% | +32.9% | +42% / +510% |
| CAICaris Life Sciences, Inc. | 7.5 bn | 76.5 | 17.2% | 9.2% | +97.0% | +2% / unavailable |
| RDNTRadNet, Inc. | 6.1 bn | — | -2.1% | -0.9% | +11.5% | −6% / +135% |
| GRALGRAIL, Inc. | 5.4 bn | — | -17.3% | -243.8% | +17.2% | +8% / unavailable |
| CDNACaredx, Inc. | 4.0 bn | 31.9 | 33.0% | 25.9% | +13.8% | +327% / +686% |
| FTREFortrea Holdings Inc. | 2.0 bn | — | -12.3% | -2.6% | +1.0% | +61% / −31% |
| VCYTVeracyte, Inc. | 1.9 bn | 15.6 | 9.4% | 21.8% | +16.0% | −49% / −6% |
| PSNLPersonalis, Inc. | 1.7 bn | — | -62.1% | -147.7% | −17.7% | +45% / +916% |
| BLLNBillionToOne, Inc. | 1.3 bn | 116.9 | 30.2% | 11.3% | +100.0% | −14% / unavailable |
| CSTLCastle Biosciences, Inc. | 1.1 bn | — | -4.9% | -6.1% | +3.7% | −14% / +71% |
| FLGTFulgent Genetics, Inc. | 521.3 m | — | -8.6% | -27.5% | +13.8% | −37% / −32% |
| YDESYD Bio Limited | 508.3 m | — | -445.1% | -1,392.6% | +16.9% | −38% / unavailable |
| BDSXBiodesix, Inc. | 220.0 m | — | -778.9% | -25.7% | +24.1% | +140% / −33% |
| XGNExagen Inc. | 184.1 m | — | -113.8% | -26.6% | +19.7% | −4% / +313% |
| SERASera Prognostics, Inc. | 60.9 m | — | -49.7% | -34,866.7% | +5.2% | −38% / +7% |
| AMSAmerican Shared Hospital Services | 7.8 m | — | -7.5% | -5.8% | −0.9% | −45% / −51% |
| MDXHMdxhealth SA | 7.8 m | — | -2,440.4% | -31.1% | +19.8% | −96% / −95% |
| ACONAclarion, Inc. | 4.5 m | — | -74.1% | -10,260.0% | +65.6% | −75% / −100% |
| ADVBAdvanced Biomed Inc. | 3.1 m | 0.4 | 84.8% | 5,231.3% | unavailable | −79% / unavailable |
| BGLCBioNexus Gene Lab Corp. | 2.5 m | — | -33.7% | -82.4% | −21.9% | −81% / −91% |
| BNRBurning Rock Biotech Limited | 0 | — | -10.1% | -10.3% | +9.2% | −39% / +60% |
1- and 3-year price returns: for ADVB from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Advanced Biomed Inc. (ADVB) has fully exited its biomedical business of cancer detection from blood samples and has refocused on FinTruth, an AI platform that verifies financial analysis produced by language models. The company reported revenue of $127,637 in fiscal 2026, while the $6,261,276 loss from continuing operations shows the shift to the new model is still at an early stage.
SWOT
Strengths
- The Smith RM reasoning engine is wholly owned by Acellent and not subject to third-party license restrictions. 1
- Internal datasets and the financial rules base have been built over time and support the verification functions. 1
- The operating structure is lean, which may limit fixed costs while the company reorients. 1
Weaknesses
- Revenue from continuing operations is very small and the operating loss remains significant. 1
- The company has limited operating experience in the AI industry, which makes its prospects hard to evaluate. 1
- Most current assets come from receivables from former affiliates, whose collection is uncertain. 1
Opportunities
- If financial institutions adopt automated verification in their workflows, the company could build recurring revenue. 1
- Partnerships with financial IT platforms and model providers could extend distribution without high sales costs. 1
- Growing explainability and audit requirements for AI in finance could create demand for verification services. 1
Threats
- Foundation-model providers could add similar verification features, reducing the value of a separate offering. 1
- Dependence on cloud providers and distribution partners could disrupt services or raise costs. 1
- A cybersecurity incident could create liability and lead to loss of financial-sector customers. 1
Risks
- Collection of receivables from former affiliateshigh
The amount owed by the former Hong Kong subsidiary was due for repayment by January 2027, and a large part of current assets depends on these collections. Delays or non-payment could affect liquidity. 1
- Dependence on additional financinghigh
The company has said it may need additional financing if collections or revenue do not develop as planned. The equity line facility was terminated in July 2026. 1
- Strategic changemedium
The company has fully changed its business model, and investors have limited information about its ability to execute the new strategy. 1
- Competition from larger providersmedium
Competitors with much greater resources could launch similar features or dominate distribution, limiting growth. 1
- Cybersecurity and compliancemedium
A cyberattack or software defect could lead to loss of customer data, contract claims, and remediation costs. 1
Investment thesis
What would need to be true (bull case)
- If financial institutions adopt AI verification quickly, the company could turn FinTruth into a source of recurring revenue. The Acellent acquisition and its data assets could provide a technical edge. 1
- Full collection of receivables from former affiliates could strengthen the balance sheet and fund product development. 1
- A lean structure and full focus on technology could allow revenue growth without a large increase in fixed costs. 1
What would break the thesis
- Revenue is very small and the loss from continuing operations shows the business model is not yet sustainable. 1
- The company depends on collections from former affiliates and on additional financing, which could limit its flexibility. 1
- The market is new, competition is intense, and model providers could make a separate verification layer less necessary. 1
What to watch
- Collection of the receivable from the former Hong Kong subsidiary and the buyer of the Taiwan subsidiary2027
- Any need for additional financing and resulting dilution for shareholders2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Advanced Biomed Inc. is a holding company incorporated in Nevada. Until 2026 it developed laboratory devices and chemicals for finding and studying cancer cells in blood, with the goal of helping doctors detect and monitor cancer through simple blood tests. In April 2026 it acquired Acellent Technologies (Hong Kong), the developer of the FinTruth platform, and its biomedical operations were sold or closed. 1
The company describes FinTruth as a verification and audit layer, not a replacement for the underlying AI model or for professional judgment. The platform checks English or Chinese reports against source documents, using its own reasoning engine, Smith RM, and produces traceable results. It is delivered as a browser-based SaaS workspace, through APIs, or as an on-premises installation at the client. 1
The operating structure is lean and technology-focused, with staff working on AI research, algorithm engineering, data, and commercialization. The company does not own data centers; the SaaS version runs on rented infrastructure from international cloud providers. Target customers include commercial banks, securities firms, insurers, asset managers, and audit firms. 1
Segments
FinTruth (AI financial verification)
FinTruth is the only product offered to customers and verifies credit reports, research reports, and financial statements. Revenue in this segment so far has come from agency service fees, serving as a proof of concept after the Acellent acquisition. 1
Biomedical operations (discontinued)
The laboratory devices and cancer research reagents were sold or abandoned in December 2025 and June 2026. Their results are reported as discontinued operations, and the gain on disposal of subsidiaries of $14,015,417 was recorded in fiscal 2026. 1
Market context
The company says the market for AI verification in finance is at an early stage, and demand depends on financial institutions' technology budgets, regulatory requirements, model performance, and integration costs. Demand is supported by the wider use of language models in credit and risk analysis, the risk of AI errors, and requirements for explainability and audit. Adoption remains uncertain and could be slow because banks and insurers have lengthy procurement processes. 1
End customers are regulated institutions that impose strict security, data-location, and audit requirements. If FinTruth cannot meet these requirements, the company could lose customers or access to parts of its target market. 1
Trends
- Adoption of language models in financetailwind
Banks, investment firms, and insurers increasingly use language models and AI agents in credit analysis, research, risk assessment, and compliance. This creates demand for independent verification of the output. 1
- AI regulationmixed
Requirements for transparency, explainability, and accountability of AI systems used in financial decisions are increasing, which could support demand for verification. New or inconsistent rules across jurisdictions could, however, raise costs and limit use cases. 1
- Foundation-model providers building verification inheadwind
Model providers could add verification and citation features directly into their models, which would reduce the need for a separate layer. The rapid pace of AI innovation could make the current technology less competitive. 1
- Cybersecurity requirementsheadwind
Financial institutions impose high standards on security and third-party risk, and cyberattacks are becoming more frequent. Compliance can be costly and can lengthen sales cycles for a small company. 1
Competitive position
The company faces foundation-model providers that could integrate verification, large technology, data, and financial information companies, financial IT platforms, and other AI start-ups. Many competitors have much greater financial, technical, and distribution resources. Some potential partners could also be competitors. 1
Claimed advantages include the proprietary Smith RM engine, owned by Acellent and not subject to third-party license restrictions, and datasets and financial rules accumulated over about three years. These assets are mainly protected through trade secrets and contracts, which offers limited protection. 1
- Foundation-model providers
Could build verification and citation directly into their models, acting as both competitors and possible distribution partners; the source does not name them.
- Large technology, data, and financial information companies
Have much larger resources and broad distribution, which could let them launch similar features; the source does not name them.
- Financial IT platforms
Could be both distribution channels and competitors; the source does not identify specific firms.
- Other AI start-ups
Compete for the same financial customers; the source does not identify them.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Annual report13 Oct 2026
- Current report17 Jul 2026Termination of a material agreement · Financial statements and exhibits
- Current report01 Jul 2026Shareholder vote
- Current report30 Jun 2026Material agreement · Financial statements and exhibits
- Proxy statement04 Jun 2026
- Quarterly report15 May 2026
- Current report01 May 2026Acquisition or disposition of assets · Item 3.02 · Departure or appointment of officers · Financial statements and exhibits
- Current report14 Apr 2026Material agreement · Financial statements and exhibits
- Current report03 Apr 2026Material agreement · Financial statements and exhibits
- Current report30 Mar 2026Departure or appointment of officers
Sources
- [1] Form 10-K, fiscal year ended 2026-06-30 · SEC / Advanced Biomed Inc. · 13 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.